Amanote Research

Amanote Research

    RegisterSign In

Blinatumomab Approval Expanded Based on MRD

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-nb2018-059
Full Text
Open PDF
Abstract

Available in full text

Categories
Oncology
Date

April 27, 2018

Authors

Unknown

Publisher

American Association for Cancer Research (AACR)


Related search

FDA Approval: Blinatumomab for Patients With B-Cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission With Minimal Residual Disease

Clinical Cancer Research
Cancer ResearchOncology
2019English

Fire Barrier Based on Expanded Perlite Composites

2019English

Highly Sensitive MRD Tests for ALL Based on the IKZF1 Δ3–6 Microdeletion

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2011English

FDA Issues Draft Guidance on MRD Testing

Cancer Discovery
Oncology
2018English

A Convenor on Approval

Bulletin of the Royal College of Psychiatrists
1980English

Blinatumomab in Acute Lymphoblastic Leukemia

Expert Review of Anticancer Therapy
OncologyPharmacology
2016English

The Network Attack Model Based on Hierarchical Expanded Stochastic Petri Net

International Journal of Security and its Applications
Computer Science
2014English

MRD Rank Metric Convolutional Codes

2017English

Trastuzumab Biosimilar on Track for Approval

Cancer Discovery
Oncology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy